2182230121822301000001792581--12-312020Q3false16391397986965949892692863812P1YP10M0000000001792581us-gaap:SeriesAPreferredStockMember2020-12-202020-12-200001792581us-gaap:CommonStockMember2019-07-012019-09-300001792581us-gaap:SeriesBPreferredStockMember2020-01-312020-01-310001792581us-gaap:SeriesBPreferredStockMember2020-01-242020-01-240001792581us-gaap:SeriesBPreferredStockMember2019-11-132019-11-130001792581us-gaap:SeriesBPreferredStockMember2019-09-132019-09-130001792581us-gaap:SeriesBPreferredStockMember2019-01-012019-12-310001792581us-gaap:SeriesAPreferredStockMember2018-12-202018-12-200001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-07-012019-09-3000017925812020-06-172020-06-1700017925812019-12-172019-12-170001792581us-gaap:RetainedEarningsMember2020-09-300001792581us-gaap:AdditionalPaidInCapitalMember2020-09-300001792581us-gaap:RetainedEarningsMember2020-06-300001792581us-gaap:AdditionalPaidInCapitalMember2020-06-3000017925812020-06-300001792581us-gaap:RetainedEarningsMember2020-03-310001792581us-gaap:AdditionalPaidInCapitalMember2020-03-3100017925812020-03-310001792581us-gaap:RetainedEarningsMember2019-12-310001792581us-gaap:AdditionalPaidInCapitalMember2019-12-310001792581us-gaap:RetainedEarningsMember2019-09-300001792581us-gaap:AdditionalPaidInCapitalMember2019-09-300001792581us-gaap:RetainedEarningsMember2019-06-300001792581us-gaap:AdditionalPaidInCapitalMember2019-06-3000017925812019-06-300001792581us-gaap:RetainedEarningsMember2019-03-310001792581us-gaap:AdditionalPaidInCapitalMember2019-03-3100017925812019-03-310001792581us-gaap:RetainedEarningsMember2018-12-310001792581us-gaap:AdditionalPaidInCapitalMember2018-12-310001792581us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-09-300001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-09-300001792581us-gaap:CommonStockMember2020-09-300001792581us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-06-300001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-06-300001792581us-gaap:CommonStockMember2020-06-300001792581us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-03-310001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2020-03-310001792581us-gaap:CommonStockMember2020-03-310001792581us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-12-310001792581us-gaap:CommonStockMember2019-12-310001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-09-300001792581us-gaap:CommonStockMember2019-09-300001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-06-300001792581us-gaap:CommonStockMember2019-06-300001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2019-03-310001792581us-gaap:CommonStockMember2019-03-310001792581us-gaap:SeriesAPreferredStockMemberus-gaap:PreferredStockMember2018-12-310001792581us-gaap:CommonStockMember2018-12-310001792581us-gaap:SubsequentEventMemberus-gaap:IPOMember2020-10-150001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2019-12-310001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2018-12-310001792581us-gaap:EmployeeStockOptionMemberkrbp:ShareBasedPaymentArrangementFourNonemployeesMemberkrbp:StockIncentivePlan2017Member2020-08-202020-08-200001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2019-09-300001792581us-gaap:RestrictedStockUnitsRSUMemberkrbp:StockIncentivePlan2017Member2017-01-310001792581srt:MinimumMemberus-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581srt:MaximumMemberus-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581srt:MinimumMemberus-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2019-01-012019-09-300001792581srt:MaximumMemberus-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2019-01-012019-09-300001792581us-gaap:WarrantMember2020-01-012020-09-300001792581us-gaap:WarrantMember2019-01-012019-09-300001792581us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001792581krbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581us-gaap:RestrictedStockUnitsRSUMemberkrbp:StockIncentivePlan2017Member2020-08-200001792581us-gaap:RestrictedStockUnitsRSUMemberkrbp:StockIncentivePlan2017Member2020-09-300001792581us-gaap:RestrictedStockUnitsRSUMemberkrbp:StockIncentivePlan2017Member2019-01-012019-09-300001792581us-gaap:RestrictedStockUnitsRSUMemberkrbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581srt:MinimumMemberus-gaap:RestrictedStockUnitsRSUMemberkrbp:MonthlyVestingConditionsMember2020-01-012020-09-300001792581srt:MinimumMemberkrbp:StockIncentivePlan2017Memberkrbp:MonthlyVestingConditionsMember2020-01-012020-09-300001792581srt:MaximumMemberus-gaap:RestrictedStockUnitsRSUMemberkrbp:MonthlyVestingConditionsMember2020-01-012020-09-300001792581srt:MaximumMemberkrbp:StockIncentivePlan2017Memberkrbp:MonthlyVestingConditionsMember2020-01-012020-09-300001792581krbp:StockIncentivePlan2017Memberkrbp:AnnualVestingConditionsMember2020-01-012020-09-300001792581krbp:SBLoanPaycheckProtectionProgramMember2020-01-012020-09-300001792581krbp:ChiefStrategyAndInnovationOfficerMember2020-01-012020-09-300001792581krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember2020-01-012020-09-300001792581krbp:ChiefStrategyAndInnovationOfficerMember2019-01-012019-09-300001792581krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember2019-01-012019-09-300001792581srt:MinimumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-01-012020-09-300001792581srt:MinimumMemberus-gaap:LeaseholdImprovementsMember2020-01-012020-09-300001792581srt:MinimumMemberus-gaap:EquipmentMember2020-01-012020-09-300001792581srt:MaximumMemberus-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-01-012020-09-300001792581srt:MaximumMemberus-gaap:LeaseholdImprovementsMember2020-01-012020-09-300001792581srt:MaximumMemberus-gaap:EquipmentMember2020-01-012020-09-300001792581srt:MinimumMember2020-01-012020-09-300001792581srt:MaximumMember2020-01-012020-09-300001792581krbp:OfficeFurnitureFixturesAndEquipmentMember2020-01-012020-09-300001792581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-09-300001792581us-gaap:LeaseholdImprovementsMember2020-09-300001792581us-gaap:EquipmentMember2020-09-300001792581us-gaap:ConstructionInProgressMember2020-09-300001792581krbp:OfficeFurnitureFixturesAndEquipmentMember2020-09-300001792581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2019-12-310001792581us-gaap:LeaseholdImprovementsMember2019-12-310001792581us-gaap:EquipmentMember2019-12-310001792581krbp:OfficeFurnitureFixturesAndEquipmentMember2019-12-3100017925812020-06-102020-06-100001792581us-gaap:SeriesBPreferredStockMember2020-06-082020-06-080001792581us-gaap:SeriesBPreferredStockMember2019-09-132020-09-3000017925812012-12-012016-05-3100017925812020-10-152020-10-150001792581us-gaap:SeriesBPreferredStockMember2020-06-300001792581srt:MaximumMemberus-gaap:SeriesBPreferredStockMember2020-01-290001792581us-gaap:SeriesBPreferredStockMember2019-09-130001792581us-gaap:SeriesAPreferredStockMember2020-09-300001792581us-gaap:PreferredStockMember2020-09-300001792581us-gaap:SeriesAPreferredStockMember2019-12-310001792581us-gaap:PreferredStockMember2019-12-3100017925812019-12-1600017925812019-12-1500017925812016-05-310001792581us-gaap:SeriesBPreferredStockMember2019-12-152019-12-150001792581us-gaap:SeriesBPreferredStockMember2020-03-310001792581us-gaap:SeriesBPreferredStockMember2019-09-300001792581us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-04-012020-06-300001792581us-gaap:SeriesBPreferredStockMember2020-04-012020-06-300001792581us-gaap:SeriesBPreferredStockMemberus-gaap:PreferredStockMember2020-01-012020-03-310001792581us-gaap:SeriesBPreferredStockMember2020-01-012020-03-310001792581us-gaap:SeriesBPreferredStockMember2019-07-012019-09-300001792581srt:MinimumMemberus-gaap:SeriesBPreferredStockMember2019-11-152019-11-150001792581us-gaap:SubsequentEventMember2020-11-190001792581us-gaap:RetainedEarningsMember2020-07-012020-09-300001792581us-gaap:RetainedEarningsMember2020-04-012020-06-300001792581us-gaap:RetainedEarningsMember2020-01-012020-03-310001792581us-gaap:RetainedEarningsMember2019-07-012019-09-300001792581us-gaap:RetainedEarningsMember2019-04-012019-06-300001792581us-gaap:RetainedEarningsMember2019-01-012019-03-310001792581srt:MaximumMember2020-09-3000017925812018-08-310001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2020-09-300001792581us-gaap:ConvertibleNotesPayableMember2018-12-310001792581us-gaap:SeriesBPreferredStockMember2019-11-160001792581us-gaap:ConvertibleNotesPayableMember2020-09-300001792581krbp:SBLoanPaycheckProtectionProgramMember2020-05-010001792581srt:MinimumMemberus-gaap:ConvertibleNotesPayableMember2016-06-300001792581srt:MaximumMemberus-gaap:ConvertibleNotesPayableMember2016-06-300001792581us-gaap:ConvertibleNotesPayableMemberus-gaap:SeriesAPreferredStockMember2019-08-150001792581us-gaap:ConvertibleNotesPayableMemberus-gaap:SeriesAPreferredStockMember2018-12-200001792581krbp:SBLoanPaycheckProtectionProgramMember2020-09-300001792581us-gaap:SeriesBPreferredStockMemberus-gaap:SubsequentEventMemberus-gaap:IPOMember2020-10-152020-10-150001792581us-gaap:SeriesAPreferredStockMemberus-gaap:SubsequentEventMemberus-gaap:IPOMember2020-10-152020-10-150001792581us-gaap:ConvertibleNotesPayableMemberus-gaap:SeriesAPreferredStockMember2018-12-202018-12-2000017925812020-09-1800017925812020-06-1700017925812019-09-2400017925812020-09-1900017925812019-09-2500017925812020-06-100001792581us-gaap:SeriesBPreferredStockMember2019-12-310001792581us-gaap:SeriesBPreferredStockMember2020-09-300001792581us-gaap:SeriesBPreferredStockMember2019-11-1300017925812019-09-3000017925812018-12-310001792581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2020-01-012020-09-300001792581us-gaap:SoftwareAndSoftwareDevelopmentCostsMember2019-01-012019-09-300001792581us-gaap:SeriesAPreferredStockMember2020-01-012020-09-300001792581us-gaap:RestrictedStockUnitsRSUMember2020-01-012020-09-300001792581us-gaap:EmployeeStockOptionMember2020-01-012020-09-300001792581us-gaap:SeriesBPreferredStockMember2019-01-012019-09-300001792581us-gaap:SeriesAPreferredStockMember2019-01-012019-09-300001792581us-gaap:EmployeeStockOptionMember2019-01-012019-09-300001792581us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ResearchAndDevelopmentExpenseMemberkrbp:StockIncentivePlan2017Member2020-07-012020-09-300001792581us-gaap:RestrictedStockUnitsRSUMemberus-gaap:GeneralAndAdministrativeExpenseMemberkrbp:StockIncentivePlan2017Member2020-07-012020-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberkrbp:StockIncentivePlan2017Member2020-07-012020-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberkrbp:StockIncentivePlan2017Member2020-07-012020-09-300001792581us-gaap:EmployeeStockOptionMemberkrbp:ShareBasedPaymentArrangementFourNonemployeesMemberus-gaap:GeneralAndAdministrativeExpenseMember2020-07-012020-09-300001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2020-07-012020-09-3000017925812020-06-082020-06-080001792581us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberkrbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberkrbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2020-01-012020-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberkrbp:StockIncentivePlan2017Member2019-07-012019-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberkrbp:StockIncentivePlan2017Member2019-07-012019-09-300001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2019-07-012019-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:ResearchAndDevelopmentExpenseMemberkrbp:StockIncentivePlan2017Member2019-01-012019-09-300001792581us-gaap:EmployeeStockOptionMemberus-gaap:GeneralAndAdministrativeExpenseMemberkrbp:StockIncentivePlan2017Member2019-01-012019-09-300001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2019-01-012019-09-300001792581us-gaap:SeriesBPreferredStockMember2020-06-102020-06-100001792581us-gaap:SeriesBPreferredStockMember2020-01-012020-09-300001792581us-gaap:AdditionalPaidInCapitalMember2020-07-012020-09-300001792581us-gaap:AdditionalPaidInCapitalMember2020-01-012020-03-3100017925812020-01-012020-03-310001792581us-gaap:AdditionalPaidInCapitalMember2019-07-012019-09-300001792581us-gaap:AdditionalPaidInCapitalMember2019-04-012019-06-3000017925812019-04-012019-06-300001792581us-gaap:AdditionalPaidInCapitalMember2019-01-012019-03-3100017925812019-01-012019-03-310001792581us-gaap:SeriesBPreferredStockMember2019-12-060001792581us-gaap:AdditionalPaidInCapitalMember2020-04-012020-06-3000017925812020-04-012020-06-300001792581us-gaap:CommonStockMember2020-04-012020-06-300001792581krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember2019-09-042019-09-040001792581krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember2018-04-182018-04-180001792581krbp:ChiefStrategyAndInnovationOfficerMember2018-07-202018-07-200001792581krbp:ChiefStrategyAndInnovationOfficerMember2020-06-192020-06-190001792581krbp:ChiefStrategyAndInnovationOfficerMember2020-06-192020-06-190001792581krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember2020-06-192020-06-190001792581krbp:ChiefFinancialOfficerAndChiefOperatingOfficerMember2020-06-192020-06-190001792581us-gaap:ShareBasedPaymentArrangementEmployeeMember2020-06-082020-06-080001792581krbp:EmployeeMember2020-06-082020-06-080001792581krbp:ChiefMedicalOfficerMember2020-06-082020-06-080001792581krbp:ChiefMedicalOfficerMember2020-06-082020-06-080001792581us-gaap:SeriesBPreferredStockMember2019-12-062019-12-0600017925812019-08-310001792581krbp:WarrantExercisableBeginningSixMonthsAfterListingDateMemberus-gaap:SeriesBPreferredStockMember2020-01-012020-09-300001792581krbp:WarrantExercisableBeginningNineMonthsAfterListingDateMemberus-gaap:SeriesBPreferredStockMember2020-01-012020-09-300001792581us-gaap:ConvertibleNotesPayableMemberus-gaap:SeriesAPreferredStockMember2020-01-012020-09-300001792581us-gaap:ConvertibleNotesPayableMemberus-gaap:SeriesAPreferredStockMember2019-08-152019-08-150001792581us-gaap:SubsequentEventMemberus-gaap:IPOMember2020-10-152020-10-150001792581us-gaap:SubsequentEventMember2020-11-192020-11-1900017925812020-06-080001792581us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementNonemployeeMemberkrbp:StockIncentivePlan2017Member2020-08-202020-08-200001792581us-gaap:RestrictedStockUnitsRSUMemberus-gaap:ShareBasedPaymentArrangementEmployeeMemberkrbp:StockIncentivePlan2017Member2020-08-202020-08-200001792581us-gaap:RestrictedStockUnitsRSUMemberkrbp:StockIncentivePlan2017Member2020-08-202020-08-200001792581us-gaap:EmployeeStockOptionMemberkrbp:StockIncentivePlan2017Member2020-08-202020-08-2000017925812020-07-012020-09-3000017925812019-07-012019-09-300001792581krbp:SBLoanPaycheckProtectionProgramMember2020-05-012020-05-010001792581us-gaap:ConvertibleNotesPayableMember2019-01-012019-09-300001792581us-gaap:ConvertibleNotesPayableMemberus-gaap:SeriesAPreferredStockMember2020-09-300001792581us-gaap:ConvertibleNotesPayableMember2019-09-300001792581us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMemberus-gaap:FairValueMeasurementsRecurringMember2019-01-012019-12-310001792581us-gaap:FairValueInputsLevel3Memberus-gaap:ConvertibleNotesPayableMemberus-gaap:FairValueMeasurementsNonrecurringMember2019-01-012019-12-310001792581us-gaap:SeriesAPreferredStockMember2018-08-1400017925812019-01-012019-09-3000017925812020-09-3000017925812019-12-3100017925812020-11-2700017925812020-01-012020-09-30iso4217:USDxbrli:sharesxbrli:sharesiso4217:USDutr:sqftxbrli:purekrbp:itemkrbp:employeekrbp:individualkrbp:agreementkrbp:Vote

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2020

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from                      to

Commission File Number: 001-39169

Kiromic BioPharma, Inc.

(Exact name of registrant as specified in its charter)

Delaware

    

46-4762913

(State or other jurisdiction of incorporation or organization)

(I.R.S. Employer Identification Number)

7707 Fannin Street, Suite 140, Houston, TX

    

77054

(Address of Principal Executive Offices)

Zip Code

(832) 968-4888

(Registrant’s telephone number)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

    

Trading symbol

    

Name of Exchange on which registered

Common Shares, par value $0.001 per share

KRBP

The Nasdaq Stock Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

    Yes      No  

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

    Yes      No  

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer  

Accelerated Filer  

Non-accelerated Filer  

Smaller Reporting Company  

Emerging Growth Company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes      No  

As of November 27, 2020, there were 7,332,999 of the registrant’s ordinary shares outstanding.

Table of Contents

Kiromic BioPharma, Inc.

Quarterly Report on Form 10-Q

Period Ended September 30, 2020

TABLE OF CONTENTS

PART I

FINANCIAL INFORMATION

   

   

Item 1.

Financial Statements

4

Condensed Consolidated Balance Sheets as of September 30, 2020, and December 31, 2019 (Unaudited)

4

Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2020, and 2019 (Unaudited)

5

Condensed Consolidated Statements of Shareholders’ Equity for the three and nine months ended September 30, 2020, and 2019 (Unaudited)

6

Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2020, and 2019 (Unaudited)

8

Notes to Condensed Consolidated Financial Statements (Unaudited)

9

Item 2.

Management’s Discussion and Analysis of Financial Condition and Results of Operations

28

Item 3.

Quantitative and Qualitative Disclosures about Market Risk

44

Item 4.

Controls and Procedures

44

PART II

OTHER INFORMATION

Item 1.

Legal Proceedings

45

Item 1A.

Risk Factors

45

Item 2.

Unregistered Sales of Equity Securities and Use of Proceeds

45

Item 3.

Defaults Upon Senior Securities

45

Item 4.

Mine Safety Disclosures

45

Item 5.

Other Information

45

Item 6.

Exhibits

45

Signatures

47

2

Table of Contents

Kiromic Biopharma, Inc.

Quarterly Report on Form 10-Q

For the quarterly period ended September 30, 2020

Cautionary Note on Forward-Looking Statements

This report contains forward-looking statements that involve substantial risks and uncertainties. We make such forward-looking statements pursuant to the safe harbor provisions of the U.S. Private Securities Litigation Reform Act, Section 21E of the Securities Exchange Act of 1934, as amended, and other federal securities laws. All statements other than statements of historical facts are forward-looking statements. The forward-looking statements are contained principally in, but not limited to, the section entitled "Management's Discussion and Analysis of Financial Condition and Results of Operations." These statements relate to future events or to our future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:

our goals and strategies;
our future business development, financial condition and results of operations;
expected changes in our revenue, costs or expenditures;
growth of and competition trends in our industry;
our expectations regarding demand for, and market acceptance of, our products;
our expectations regarding our relationships with investors, institutional funding partners and other parties we collaborate with;
fluctuations in general economic and business conditions in the markets in which we operate; including those fluctuations caused by COVID-19; and
relevant government policies and regulations relating to our industry.

In some cases, you can identify forward-looking statements by terms such as “may,” “could,” “will,” “should,” “would,” “expect,” “plan,” “intend,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “project” or “continue” or the negative of these terms or other comparable terminology. These statements are only predictions. You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties and other factors, which are, in some cases, beyond our control and which could materially affect results. Factors that may cause actual results to differ materially from current expectations include, among other things, those listed under the heading “Risk Factors” included in our Registration Statement on Form S-1 (file no. 333-238153), originally filed with the Securities and Exchange Commission on May 11, 2020, as amended, and elsewhere in this report. If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements. No forward-looking statement is a guarantee of future performance.

The forward-looking statements made in this report relate only to events or information as of the date on which the statements are made in this report. Except as expressly required by the federal securities laws, there is no undertaking to publicly update or revise any forward-looking statements, whether as a result of new information, future events, changed circumstances or any other reason.

3

Table of Contents

PART I —FINANCIAL INFORMATION

Item 1. Financial Statements

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Balance Sheets

(Unaudited)

    

September 30, 

    

December 31, 

2020

2019

Assets

 

  

 

  

Current Assets:

 

  

 

  

Cash and cash equivalents

$

469,300

$

1,929,100

Inventories

 

22,200

 

22,200

Prepaid expenses and other current assets

 

1,051,900

 

89,100

Total current assets

 

1,543,400

 

2,040,400

Property and equipment, net

 

1,612,300

 

587,900

Other assets

 

24,400

 

24,400

Total Assets

$

3,180,100

$

2,652,700

Liabilities and Stockholders’ Equity:

 

  

 

  

Current Liabilities:

 

  

 

  

Accounts payable

$

1,672,900

$

452,400

Accrued expenses and other current liabilities

 

473,000

 

221,300

Loan payable

 

105,600

 

Total current liabilities

 

2,251,500

 

673,700

Total Liabilities

 

2,251,500

 

673,700

Commitments and contingencies (Note 8)

 

  

 

  

Stockholders’ Equity:

 

  

 

  

Series A‑1 Preferred Stock, $0.0001 par value: 24,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 21,822,301 shares issued and outstanding as of September 30, 2020 and December 31, 2019

 

9,134,700

 

9,134,700

Series B Preferred Stock, $0.0001 par value: 16,500,000 and 14,130,435 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 16,391,397 and 9,869,659 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

 

2,331,300

 

1,306,900

Preferred Stock, $0.0001 par value: 19,500,000 and 21,869,565 shares authorized as of September 30, 2020 and December 31, 2019, respectively; 0 shares issued and outstanding as of September 30, 2020 and December 31, 2019

 

 

Common stock: 300,000,000 shares authorized as of September 30, 2020 and December 31, 2019; 4,989,269 and 2,863,812 shares issued and outstanding as of September 30, 2020 and December 31, 2019, respectively

 

 

Additional paid-in capital

 

27,525,500

 

13,965,000

Accumulated deficit

 

(38,062,900)

 

(22,427,600)

Total Stockholders’ Equity

 

928,600

 

1,979,000

Total Liabilities and Stockholders’ Equity

$

3,180,100

$

2,652,700

See accompanying notes to the condensed consolidated financial statements

4

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Operations

(Unaudited)

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2020

    

2019

    

2020

    

2019

Operating expenses:

 

  

 

  

 

  

 

  

Research and development

 

$

1,225,700

$

272,100

$

3,526,100

$

601,500

General and administrative

 

1,190,000

 

607,400

 

12,109,200

 

934,300

Total operating expenses

 

2,415,700

 

879,500

 

15,635,300

 

1,535,800

Loss from operations

 

(2,415,700)

 

(879,500)

 

(15,635,300)

 

(1,535,800)

Other expense

 

  

 

  

 

  

 

  

Interest expense

 

 

(7,400)

 

 

(22,400)

Total other expense

 

 

(7,400)

 

 

(22,400)

Net loss

 

$

(2,415,700)

$

(886,900)

$

(15,635,300)

$

(1,558,200)

Net loss per share, basic and diluted

 

$

(0.65)

$

(0.32)

$

(4.39)

$

(0.55)

Weighted average common shares outstanding, basic and diluted

 

3,719,132

 

2,862,523

 

3,719,132

 

2,862,523

See accompanying notes to the condensed consolidated financial statements

5

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited)

Three and Nine Months Ended September 30, 2020

Series A1

Series B

 

Preferred Stock

Preferred Stock

Common Stock

 

Additional Paid-

Number of

Number of

Number of

In

Accumulated

 

    

Shares

    

Amount

    

Shares

    

Amount

    

Shares

    

Amount

    

Capital

    

Deficit

Total

Balance at December 31, 2019

 

21,822,301

$

9,134,700

 

9,869,659

$

1,306,900

 

2,863,812

$

$

13,965,000

$

(22,427,600)

$

1,979,000

Issuance of Series B Preferred Stock

 

 

 

6,521,738

 

331,700

 

 

 

 

 

331,700

Series B Preferred Stock discount amortization

 

 

 

 

368,400

 

 

 

(368,400)

 

 

Warrants underlying Series B Preferred Stock issuance

 

 

 

 

 

 

 

2,668,300

 

 

2,668,300

Stock compensation expense

 

 

 

 

 

 

 

456,000

 

 

456,000

Net loss

 

 

 

 

 

 

 

 

(1,852,700)

 

(1,852,700)

Balance at March 31, 2020

 

21,822,301

 

9,134,700

 

16,391,397

$

2,007,000

 

2,863,812

$

$

16,720,900

$

(24,280,300)

$

3,582,300

Series B Preferred Stock discount amortization

 

 

 

 

324,300

 

 

 

(324,300)

 

 

Exercise of warrants

 

 

 

 

 

1,399,921

 

 

4,900

 

 

4,900

Common stock issuance to employees and non-employees

 

 

 

 

 

725,536

 

 

9,432,000

 

 

9,432,000

Stock compensation expense

 

 

 

 

 

 

 

443,000

 

 

443,000

Net loss

 

 

 

 

 

 

 

 

(11,366,900)

 

(11,366,900)

Balance at June 30, 2020

 

21,822,301

 

9,134,700

 

16,391,397

$

2,331,300

 

4,989,269

$

$

26,276,500

$

(35,647,200)

$

2,095,300

Stock compensation expense

 

 

 

 

 

 

 

1,249,000

 

 

1,249,000

Net loss

 

 

 

 

 

 

 

 

(2,415,700)

 

(2,415,700)

Balance at September 30, 2020

 

21,822,301

$

9,134,700

 

16,391,397

$

2,331,300

 

4,989,269

 

 

27,525,500

 

(38,062,900)

 

928,600

6

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Shareholders’ Equity

(Unaudited)

Three and Nine Months Ended September 30, 2019

Series A1

 

Preferred Stock

Common Stock

Additional

Accumulated

 

    

Shares

    

Amount

    

Shares

    

Amount

    

Paid-In Capital

    

Deficit

    

Total

Balance at January 1, 2019

20,886,782

$

8,727,400

 

2,862,093

$

$

10,237,600

$

(18,699,700)

$

265,300

 

Stock compensation expense

 

 

 

 

 

104,000

 

 

104,000

Net loss

 

 

 

 

 

 

(390,900)

 

(390,900)

Balance at March 31, 2019

 

20,886,782

$

8,727,400

 

2,862,093

$

$

10,341,600

$

(19,090,600)

$

(21,600)

Stock compensation expense

 

 

 

 

 

105,000

 

 

105,000

Net loss

 

 

 

 

 

 

(280,400)

 

(280,400)

Balance at June 30, 2019

 

20,886,782

$

8,727,400

 

2,862,093

 

 

10,446,600

 

(19,371,000)

 

(197,000)

Conversion of convertible promissory notes and accrued interest into Series A‑1 Preferred Stock

 

935,519

407,300

 

 

 

 

 

407,300

Warrants underlying Series B Preferred Stock issuance

 

 

 

 

 

1,202,500

 

 

1,202,500

Series B Preferred Stock discount amortization

 

 

 

  

 

 

(16,400)

 

 

(16,400)

Exercised stock options

 

 

 

1,432

 

 

9,500

 

 

9,500

Stock compensation expense

 

 

 

  

 

 

160,000

 

 

160,000

Net loss

 

 

 

  

 

 

 

(886,900)

 

(886,900)

Balance at September 30, 2019

 

21,822,301

$

9,134,700

 

2,863,525

 

 

11,802,200

 

(20,257,900)

 

679,000

See accompanying notes to the condensed consolidated financial statements

7

Table of Contents

KIROMIC BIOPHARMA, INC.

Condensed Consolidated Statements of Cash Flows

(Unaudited)

Nine Months Ended

September 30, 

    

2020

    

2019

Cash flows from operating activities:

 

  

 

  

Net loss

$

(15,635,300)

$

(1,558,200)

Adjustments to reconcile net loss to net cash used for operating activities:

 

  

 

  

Depreciation

 

118,900

 

63,700

Stock compensation expense

 

11,580,000

 

369,000

Non-cash interest

 

 

20,500

Changes in operating assets and liabilities:

 

  

 

  

Unbilled receivables from granting agency

 

 

5,000

Inventories

 

 

(5,900)

Prepaid expenses and other current assets

 

(149,800)

 

34,800

Accounts payable

 

398,300

 

226,100

Accrued expenses and other current liabilities

 

130,700

 

(138,900)

Deferred rent

 

 

(19,000)

Convertible promissory notes derivative liability

 

 

2,000

Net cash used for operating activities

 

(3,557,200)

 

(1,000,900)

Cash flows from investing activities:

 

  

 

  

Purchases of property and equipment

 

(1,013,100)

 

(26,500)

Net cash used for investing activities

 

(1,013,100)

 

(26,500)

Cash flows from financing activities:

 

  

 

  

Proceeds from sale of convertible promissory notes

 

 

250,000

Exercise of stock options

 

 

9,500

Proceeds from warrant exercise

 

4,900

 

Proceeds from loan payable

 

115,600

 

Loan repayments

 

(10,000)

 

  

Proceeds from Series B Preferred Stock issuance

 

3,000,000

 

1,571,400

Net cash provided by financing activities

 

3,110,500

 

1,830,900

Net change in cash and cash equivalents

 

(1,459,800)

 

803,500

Cash and cash equivalents:

 

 

  

Beginning of year

 

1,929,100

 

384,300

End of period

$

469,300

$

1,187,800

Supplemental disclosures of non-cash investing and financing activities:

 

  

 

  

Accruals for property and equipment

$

130,200

$

74,700

Conversion of accounts payable into convertible promissory notes

$

$

134,800

Conversion of convertible promissory notes and accrued interest into Series A‑1 Preferred Stock

 

$

407,300

Accruals for deferred initial public offering costs

$

813,000

$

Warrants underlying Series B Preferred Stock issuance

$

2,668,300

$

See accompanying notes to the condensed consolidated financial statements

8

Table of Contents

KIROMIC BIOPHARMA, INC.

Notes to Condensed Consolidated Financial Statements

(Unaudited)

1.ORGANIZATION

Nature of Business

Kiromic BioPharma, Inc. and subsidiary (the "Company") is a preclinical stage biopharmaceutical company formed under the Texas Business Organizations Code in December 2012. On May 27, 2016, the Company converted from a Texas limited liability company into a Delaware corporation and changed its name from Kiromic LLC to Kiromic Inc. On December 16, 2019, the Company amended and restated its certificate of incorporation charter to re-name the company, Kiromic BioPharma, Inc.

The Company is focused on discovering, developing, and commercializing novel immune-oncology therapy applications through its robust product pipeline, which are in the pre initial new drug validation stages of the US Food and Drug Administration clinical trial process. The Company maintains offices in Houston, Texas. The Company has not generated any revenues to date.

The Company’s wholly-owned subsidiary, GreenPlanet Pharma, Inc., operates an oral healthcare business. It has developed a mouthwash using a high quality, safe, and natural ingredient formulation to provide effective symptomatic relief for a wide range of oral irritations and health concerns. This business is recently formed and the product was recently developed. This business has not generated any revenues.

Going Concern—These condensed consolidated financial statements have been prepared on a going concern basis, which implies the Company will continue to realize its assets and discharge its liabilities in the normal course of business. The Company has incurred significant losses and negative cash flows from operations since inception and expects to incur additional losses until such time that it can generate significant revenue from the commercialization of its product candidates. The Company had negative cash flow from operations of $3,557,200 for the nine months ended September 30, 2020, and an accumulated deficit of $38,062,900 as of September 30, 2020. Although the Company completed its initial public offering on October 15, 2020 and received net proceeds of $12,372,700, the Company does not have sufficient cash on hand or available liquidity to meet its obligations through the 12 months following the date the condensed consolidated financial statements are issued. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

To date, the Company has relied on equity and debt financing to fund its operations. The Company’s product candidates are still in the early stages of development, and substantial additional financing will be needed by the Company to fund its operations and ongoing research and development efforts prior to the commercialization, if any, of its product candidates. Given its projected operating requirements and its existing cash and cash equivalents, the Company plans to complete an additional financing transaction in the first half of 2021 in order to continue operations. Management is currently evaluating different strategies to obtain the required funding of future operations. These strategies may include, but are not limited to, additional funding from current or new investors. However, there can be no assurance that the Company will be able to secure such additional financing, or if available, that it will be sufficient to meet its needs or on favorable terms. Therefore, the plans cannot be deemed probable. As a result, the Company has concluded that management’s plans do not alleviate substantial doubt about the Company’s ability to continue as a going concern.

The condensed consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might result from the outcome of this uncertainty.

NIH Grant—In August 2018, the National Institute of Health ("the NIH"), the primary agency of the US government responsible for biomedical and public health research, awarded a Phase I/II grant to the Company in the amount of $2,235,000 for the development and non-clinical testing of a new anti-arteriosclerosis gene therapy delivered by engineered adeno-associated viral vectors. Phase I of the grant approved amounts of $851,000 and covered the period September 2018 through August 2019, entitled the Company to reimbursement for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees. The Company did not complete Phase I by August 2019, but was granted an extension to complete Phase I by the NIH through August 2021. Starting after Phase 1 completion in 2021, Phase II of the grant covers reimbursements for certain salaries and wages, materials and supplies, facilities and administrative costs, and fixed fees of $1,384,000.

9

Table of Contents

2.SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The accompanying condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("GAAP") for interim financial information (Accounting Standards Codification ("ASC") 270, Interim Reporting) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity GAAP. Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of the Company for the periods presented.

All intercompany balances were eliminated upon consolidation.

On December 17, 2019, the Company completed a 1-for-10 reverse stock split of its outstanding common stock. On June 17, 2020, the Company completed a 1-for-3.494 reverse stock split of its outstanding common stock. Accordingly, unless otherwise noted, all share and per share information has been restated to retroactively show the effect of these stock splits.

Use of Estimates—The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Significant estimates include determination of the fair value of common stock and related stock-based compensation, the fair value of convertible promissory notes and the related embedded derivative liability, warrants to purchase common stock underlying shares of Series B Preferred Stock, and estimating services incurred by third-party service providers used to recognize research and development expense.

Cash and Cash Equivalents—As of September 30, 2020 and December 31, 2019, cash and cash equivalents consisted entirely of cash on hand and bank deposits. The Company considers all highly liquid instruments with remaining maturities at purchase of 90 days or less to be cash equivalents.

Unbilled Receivables from Granting Agency—Unbilled receivables include certain cost reimbursements owed to the Company resulting from a biomedical research grant from the NIH. Direct costs subject to reimbursement are recorded only after actual expenses have been incurred while indirect costs are calculated using the percentage-of-completion accounting method. Unbilled receivables represent qualified cost reimbursements for which reimbursement have not yet been requested from or billed to the NIH due to the timing of the accounting invoicing cycle. The Company estimates the amount of probable credit losses from its existing unbilled receivables in the form of an allowance for doubtful accounts. The Company determines the allowance for doubtful accounts based upon an aging of unbilled receivables, historical experience, and management judgment. Unbilled receivable balances are reviewed individually for collectability. For the three and nine months ended September 30, 2020 and 2019, the Company has not experienced any credit-related losses.

Concentrations of Credit Risk and Other Uncertainties—Financial instruments that potentially subject the Company to concentration of credit risk consist of cash and cash equivalents. Substantially all of the Company’s cash and cash equivalents were deposited in accounts at a small number of national financial institutions. Account balances may at times exceed federally-insured limits. The Company has not incurred losses related to these cash and cash equivalents deposited at financial institutions and management believes that the Company is not exposed to significant credit risk due to the financial strength of the depository institutions in which the cash is held.

10

Table of Contents

The Company is subject to certain risks and uncertainties from changes in any of the following areas that the Company believes could have a material adverse effect on future financial position or results of operations: the ability to obtain regulatory approval and market acceptance of, and reimbursement for, the Company’s product candidates; the performance of third-party clinical research organizations and manufacturers; protection of the intellectual property; litigation or claims against the Company based on intellectual property, patent, product, regulatory or other factors; the Company’s ability to attract and retain employees necessary to support commercial success; and changes in the industry or customer requirements including the emergence of competitive products with new capabilities.

The Company records receivables resulting from activities under its research grant from the NIH. Management believes that the Company is not exposed to significant credit risk due to the financial strength of the granting agency.

Deposit—In connection with one of the Company’s facility leases, a deposit is held by the lessor per the terms of the noncancelable agreement. The deposit has been recorded as a long-term asset on the Company’s condensed consolidated balance sheets.

Inventories—Inventories consist entirely of finished products. The balances presented are stated at the lower of cost or market and is determined using the first-in, first-out method. The Company’s policy is to write down inventory that has become obsolete, inventory that has a cost basis in excess of its expected net realizable value, and inventory quantity in excess of expected requirements. The estimate of write downs to inventory from obsolescence, costs in excess of inventory net realizable value, and inventory quantity in excess of expected requirements is subjective and primarily dependent on the estimates of future demand for a particular product. Adjustments generally increase as demand decreases due to market conditions and product life-cycle changes. As of September 30, 2020 and December 31, 2019, no such adjustments have been recorded.

Deferred Initial Public Offering Costs—In the nine months ended September 30, 2020, the Company began incurring costs in connection with the filing of a Registration Statement on Form S-1/A for an initial public offering, which are deferred in other current assets in accordance with ASC 505-10-25 in the condensed consolidated balance sheets. Initial public offering costs consist of legal, accounting, and other costs directly related to the Company’s efforts to raise capital. As of September 30, 2020, $933,100 of deferred costs related to the initial public offering were classified as other current assets on the condensed consolidated balance sheets.

Property and Equipment—Property and equipment are recorded at cost and depreciated using the straight-line method over the estimated useful lives of the assets ranging from 1 to 8 years. Major replacements and improvements are capitalized as leasehold improvements, while general repairs and maintenance are expensed as incurred. Estimated useful lives of leasehold improvements are the shorter of the remaining lease term or the estimated useful economic life of the specific asset.

Estimated useful lives of property and equipment are as follows for the major classes of assets:

Asset Description

    

Estimated Lives

Laboratory Equipment

 

3 - 8

Leasehold Improvements

 

1 - 7

Office Furniture, Fixtures, and Equipment

 

5

Software

 

3 - 5

Internal Use Software Development Costs—The Company capitalizes certain costs incurred to develop internal use software. All costs incurred that relate to planning and post-implementation phases of development are expensed as incurred. Costs incurred in the development and implementation phases are capitalized and amortized over the estimated life of the software, generally five years. The Company capitalized software development costs of approximately $10,200 and $20,000 for the nine months ended September 30, 2020 and 2019, respectively.

11

Table of Contents

Impairment of Long-Lived Assets—The Company reviews its long-lived assets, including property and equipment, for impairment indicators. If indicators are noted, the Company compares the carrying amount of the asset to its estimated undiscounted cash flows. If the carrying amount exceeds its estimated undiscounted cash flows, an impairment loss is recognized to adjust the long-lived asset to fair value. There has been no impairment losses on the Company’s long-lived assets since inception.

Comprehensive Loss—Comprehensive loss includes net loss as well as other changes in stockholders’ equity that result from transactions and economic events other than those with stockholders. For all periods presented, there was no difference between net loss and comprehensive loss.

Income Taxes—The Company files federal and state income tax returns, utilizing the accrual basis of accounting. Income taxes are provided for the tax effects of transactions reported in the condensed consolidated financial statements and consist of taxes currently due and deferred taxes. Certain transactions of the Company may be subject to accounting methods for income tax purposes, which differ from the accounting methods used in preparing these condensed consolidated financial statements in accordance with GAAP. Accordingly, the net income or loss of the Company reported for income tax purposes may differ from the balances reported for those same items in the accompanying condensed consolidated financial statements.

Deferred tax assets and liabilities are recognized for the future tax consequences attributable between the financial statement carrying amounts of existing assets and liabilities and their respective tax basis. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which such temporary differences are expected to be recovered or settled. The Company records valuation allowances to reduce deferred income tax assets to the amount that is more likely than not to be realized.

The Company records uncertain tax positions in accordance with ASC 740, Income Taxes, on the basis of a two-step process in which (1) the Company determines whether it is more-likely-than-not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority. The Company recognizes interest and penalties related to unrecognized tax benefits on the income tax expense line in the accompanying condensed consolidated statements of operations. No such interest or penalties were recognized during the three and nine months ended September 30, 2020 and 2019.

Research and Development Expense—The Company expenses research and development costs as incurred. Research and development expenses include personnel and personnel-related costs, costs associated with the Company’s pre-clinical development activities including costs of outside consultants and contractors, the submission and maintenance of regulatory filings, equipment and supplies used in developing products prior to market approval and an allocation of certain overhead costs such as facility and related expenses.

The Company accrues and expenses costs of services provided by contract research organizations in connection with preclinical studies and contract manufacturing organizations engaged to manufacture clinical trial material, costs of licensing technology, and costs of services provided by research organizations and service providers. Upfront payments and milestone payments made for the licensing of technology are expensed as research and development in the period in which they are incurred if the technology is not expected to have any alternative future uses other than the specific research and development project for which it was intended. Nonrefundable advance payments for goods or services to be received in the future for use in research and development activities are recorded as prepaid expenses. The prepaid amounts are expensed as the related goods are delivered or the services are performed rather than when the payment is made.

Proceeds from Grants—During the three months ended September 30, 2020 and 2019, the Company recognized $142,400 and $51,600, respectively, as reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH. During the nine months ended September 30, 2020 and 2019, the Company recognized $142,400 and $239,900, respectively, as reductions to research and development expense within the condensed consolidated statements of operations pursuant to its grant from the NIH.

Convertible Promissory Notes Derivative Liability—The Company has recorded an embedded derivative liability related to the discount on the per share selling price the holders of the convertible promissory notes would receive at the time of conversion in connection with the Company’s next equity financing ("the Next Financing Close"). The embedded derivative liability is initially recorded at fair value, with gains and losses arising from changes in fair value

12

Table of Contents

recognized in interest expense in the condensed consolidated statements of operations at each period end while such instruments are outstanding. The embedded derivative liability is valued using a probability weighted expected return model. See Note 7.

Upon repurchase of convertible promissory notes, ASC 470, Debt with conversion and other options, requires the Company to allocate total settlement consideration, inclusive of transaction costs, amongst the liability components of the instrument based on the fair value of the liability component immediately prior to repurchase. The difference between the settlement consideration allocated to the liability component and the net carrying value of the liability component would be recognized as gain (loss) on extinguishment of debt in the condensed consolidated statements of operations.

Fair Value Measurements—The carrying value of the Company’s cash and cash equivalents, unbilled receivables from the granting agency, prepaid expenses and other assets, accounts payable, accrued expenses and other current liabilities approximate their fair value due to their short-term nature.

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. In estimating the fair value of an asset or a liability, the Company takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date.

The Company accounts for financial instruments in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 establishes a fair value hierarchy that prioritizes the inputs to valuation techniques used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurements) and the lowest priority to unobservable inputs (Level 3 measurements). The three levels of the fair value hierarchy under ASC 820 are described below:

Level 1—Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.

Level 2—Quoted prices in non-active markets or in active markets for similar assets or liabilities, observable inputs other than quoted prices, and inputs that are not directly observable but are corroborated by observable market data.

Level 3—Prices or valuations that require inputs that are both significant to the fair value measurement and unobservable.

There were no changes in the fair value hierarchy levels during the nine months ended September 30, 2020 and 2019.

The Company’s liabilities that were measured at fair value on a non-recurring and recurring basis converted into Series A-1 Preferred Stock as of September 30, 2020 and December 31, 2019. Per ASC 820, the fair values of the convertible promissory notes are measured on a non-recurring basis at the relevant measurement date. The fair value of convertible promissory notes embedded derivative liability is measured on a recurring basis at the end of each reporting period.

13

Table of Contents

Rollforward of Level 3 Liabilities Measured at Fair Value on a Non-Recurring Basis:

    

September 30, 

    

December 31, 

2020

2019

Convertible promissory notes

 

  

 

  

Beginning balance

$

$

Amounts allocated to the embedded derivative liability at inception (at fair value)

 

 

(21,000)

Conversions from accounts payable into convertible promissory notes

 

 

134,800

Proceeds from issuances of convertible promissory notes

 

 

250,000

Conversions into Series A‑1 Stock

 

 

(363,800)

Ending balance

$

$

Rollforward of Level 3 Liabilities Measured at Fair Value on a Recurring Basis:

Convertible promissory note embedded derivative liability

 

  

 

  

Beginning balance

$

$

Realized and unrealized gains and losses

 

 

2,000

Fair value of embedded derivative liability at inception

 

 

21,000

Amounts derecognized upon conversion of the related convertible promissory notes

 

 

(23,000)

Ending balance

$

$

Nonvested Stock Options and Restricted Stock Units—Pursuant to the Company’s 2017 Stock Incentive Plan (the “Plan”), the Company has the ability to issue a variety of share-based payments and incentives to members, employees, and non-employees through grants of nonvested stock options.

The vesting conditions for stock options include annual, and monthly. Annual vesting conditions are for four years. Monthly vesting conditions range from 10 to 48 months. When nonvested options are vested, they become exercisable over a 10 year period from grant date.

The vesting conditions for restricted stock units include cliff vesting conditions. Certain restricted stock units vest with a range of 6 to 12 months following the expiration of employee lock-up agreements. Certain restricted stock units vest based on the later of achievement of key milestones or the expiration of employee lock-up agreements. When nonvested restricted stock units are vested, they become exercisable over a 10 year period from grant date.

Stock-Based Compensation—The Company records stock compensation expense related to the Plan in accordance with ASC 718, Compensation—Stock Compensation. The Company measures and recognizes stock compensation expense for all stock-based awards, including stock options, based on estimated fair values recognized using cliff vesting or the straight-line method over the requisite service period. The fair value of stock options is estimated on the grant date using the Black-Scholes option-valuation model (the “Black-Scholes model”). The calculation of stock-based compensation expense requires that the Company make assumptions and judgments about the variables used in the Black-Scholes model, including the fair value of the Company’s common stock, expected term, expected volatility of the underlying common stock, and risk-free interest rate. Forfeitures are accounted for when they occur.

The board of directors’ approach to estimating the fair value of the Company’s common stock includes utilizing methods outlined in the American Institute of Certified Public Accountants’ Practice Aid, Valuation of Privately- Held Company Equity Securities Issued as Compensation.

The Company estimates the grant-date fair value of stock options using the Black-Scholes model and the assumptions used to value such stock options are determined as follows:

Expected Term. The expected term represents the period that the Company’s stock options are expected to be outstanding. Due to limitations on the sale or transfer of the Company’s common stock as a privately held company, the Company does not believe its historical exercise pattern is indicative of the pattern it will experience as a future publicly traded company. The Company has consequently used the Staff Accounting Bulletin (“SAB”) No. 110, simplified method to calculate the expected term, which is the average of the contractual term and vesting period. The Company plans to continue to use the SAB 110 simplified method until it has sufficient trading history as a publicly traded company.

14

Table of Contents

Risk-Free Interest Rate. The Company bases the risk-free interest rate used in the Black-Scholes model on the implied yield available on US Treasury zero-coupon issues with a term equivalent to that of the expected term of the stock options for each stock option group.

Volatility. The Company determines the price volatility based on the historical volatilities of industry peers as it has no trading history for its common stock price. The Company intends to continue to consistently apply this process using the same or a similar peer group of public companies, until a sufficient amount of historical information regarding the volatility of its own common stock price becomes available, or unless circumstances change such that the identified peer companies are no longer similar, in which case other suitable peer companies whose common stock prices are publicly available would be utilized in the calculation.

Dividend Yield. The expected dividend assumption is based on the Company’s current expectations about its anticipated dividend policy. To date, the Company has not declared any dividends and, therefore, the Company has used an expected dividend yield of zero.

Common Stock Valuations. The fair value of the common stock underlying the Company’s stock-based compensation grants has historically been determined by the Company’s board of directors, with input from management and third-party valuations. The Company believes that the board of directors has the relevant experience and expertise to determine the fair value of the Company’s common stock. Given the absence of a public trading market of the Company’s common stock, and in accordance with the American Institute of Certified Public Accountants Practice Aid, Valuation of Privately-Held Company Equity Securities Issued as Compensation, the board of directors exercised reasonable judgment and considered numerous objective and subjective factors to determine the best estimate of the fair value of the Company’s common stock at each grant date. These factors include:

valuations of the common stock performed by third-party specialists;
the prices, rights, preferences, and privileges of the Company’s Series A-1 Preferred Stock and Series B Preferred Stock relative to those of the Company’s common stock;
lack of marketability of the common stock;
current business conditions and projections;
hiring of key personnel and the experience of management;
the Company’s stage of development;
likelihood of achieving a liquidity event, such as an initial public offering, a merger or acquisition of the Company given prevailing market conditions, or other liquidation event;
the market performance of comparable publicly traded companies; and
the US and global capital market conditions.

In valuing the common stock, the board of directors determined the equity value of the Company’s business using various valuation methods including combinations of income and market approaches. The income approach estimates value based on the expectation of future cash flows that a company will generate. These future cash flows are discounted to their present values using a discount rate derived from an analysis of the cost of capital of comparable publicly traded companies in the Company’s industry or similar business operations as of each valuation date and is adjusted to reflect the risks inherent in the Company’s cash flows. The market approach references actual transactions involving (i) the subject being valued, or (ii) similar assets and/or enterprises.

For each valuation, the equity value determined by the income and market approaches was then allocated to the common stock using either the option pricing method (“OPM”) or probability—weighted expected return model (“PWERM”).

The option pricing method is based on the Black-Scholes option valuation model, which allows for the identification of a range of possible future outcomes, each with an associated probability. The OPM is appropriate to use when the range of possible future outcomes is difficult to predict and thus creates highly speculative forecasts. In general, while simple in its application, management did not use the OPM approach when considering allocation techniques for the valuation of

15

Table of Contents

equity interests in early stage, privately held life science companies. Management determined that applying the OPM would violate the major assumptions of the Black Scholes option valuation model approach. Additionally, the simulation approach can generally be reasonably approximated by a scenario-based approach like the PWERM as described below.

PWERM involves a forward-looking analysis of the possible future outcomes of the enterprise. This method is particularly useful when discrete future outcomes can be predicted at a relatively high confidence level with a probability distribution. Discrete future outcomes considered under the PWERM include an initial public offering, as well as non- initial public offering market-based outcomes. Determining the fair value of the enterprise using the PWERM requires the Company to develop assumptions and estimates for both the probability of an initial public offering liquidity event and stay private outcomes, as well as the values the Company expects those outcomes could yield. Since February 2018, the Company has valued its common stock based on a PWERM.

Application of the Company’s approach involves the use of estimates, judgment, and assumptions that are highly complex and subjective, such as those regarding expected future revenue, expenses, and future cash flows, discount rates, market multiples, the selection of comparable companies, and the probability of possible future events. Changes in any or all of these estimates and assumptions or the relationships between those assumptions impact valuations as of each valuation date and may have a material impact on the valuation of the common stock.

For valuations after the completion of an initial public offering, the board of directors will determine the fair value of each share of underlying common stock based on the closing price of the common stock as reported on the date of grant. Future expense amounts for any particular period could be affected by changes in assumptions or market conditions.

Segment Data—The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Recently Issued Accounting Pronouncements—From time to time, new accounting pronouncements are issued by the Financial Accounting Standards Board (“FASB”) or other standard setting bodies and adopted by the Company as of the specified effective date. Unless otherwise discussed, the impact of recently issued standards that are not yet effective will not have a material impact on the Company’s financial position, results of operations, or cash flows upon adoption.

In February 2016, the FASB issued Accounting Standards Update (“ASU”) No. 2016-02, Leases (Topic 842), which requires lessees to recognize the following for all leases (with the exception of short-term leases) at the commencement date: a lease liability, which is a lessee’s obligation to make lease payments arising from a lease, measured on a discounted basis; and a right-of-use asset, which is an asset that represents the lessee’s right to use, or control the use of, a specified asset for the lease term. In July 2018, the FASB issued ASU 2018-11 to amend certain aspects of Topic 842. These amendments provide entities with an additional (and optional) transition method to adopt Topic 842. Under this transition method, an entity initially applies the transition requirements in Topic 842 at that Topic’s effective date with the effects of initially applying Topic 842 recognized as a cumulative effect adjustment to the opening balance of retained earnings (or other components of equity or net assets, as appropriate) in the period of adoption. On October 16, 2019, the FASB changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2022. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

In June 2016, FASB issued ASU 2016-13, Financial Instruments—Credit Losses (Topic 326). The amendments in ASU 2016-13 affect entities holding financial assets and net investment in leases that are not accounted for at fair value through net income. The amendments affect loans, debt securities, trade receivables, net investments in leases, off-balance-sheet credit exposures, reinsurance receivables, and any other financial assets not excluded from the scope that have the contractual right to receive cash. The amendments in ASU 2016-13 require a financial asset (or a group of financial assets) measured at amortized cost basis to be presented at the net amount expected to be collected. The allowance for credit losses is a valuation account that is deducted from the amortized cost basis of the financial asset(s) to present the net carrying value at the amount expected to be collected on the financial asset. On October 16, 2019, the FASB has changed the effective date of this standard applicable to the Company as an emerging growth company to January 1, 2023. The Company is currently evaluating the potential impact of this standard on its financial position, results of operations, and cash flows.

On January 1, 2019, the Company adopted ASU 2016-15 (Topic 230), Classification of Certain Cash Receipts and Payments, a new standard providing guidance on statement of cash flow classification on specific issues. The standard is effective for financial statements issued for fiscal periods beginning after December 15, 2018. It is required to be applied

16

Table of Contents

on a retrospective approach. The Company determined that this standard had no impact on its financial position, results of operations, and cash flows for the year ended December 31, 2019.

3.NET LOSS PER COMMON SHARE

Basic and diluted net loss per common share is determined by dividing net loss less deemed dividends by the weighted-average common shares outstanding during the period. For all periods presented, the common shares underlying the stock options, convertible Series A-1 Preferred Stock, and the convertible Series B Preferred Stock have been excluded from the calculation because their effect would be anti-dilutive. Therefore, the weighted-average common shares outstanding used to calculate both basic and diluted loss per common shares are the same. The following table illustrates the computation of basic and diluted earnings per share:

Three Months Ended

Nine Months Ended

September 30, 

September 30, 

    

2020

    

2019

    

2020

    

2019

Net loss

$

(2,415,700)

$

(886,900)

$

(15,635,300)

$

(1,558,200)

Less: Series B Preferred Stock discount amortization

 

 

(16,400)

 

(692,700)

 

(16,400)

Net loss attributable to common shareholders, basic and diluted

$

(2,415,700)

$

(903,300)

$

(16,328,000)

$

(1,574,600)

Weighted average common shares outstanding, basic and diluted

 

3,719,132

 

2,862,523

 

3,719,132

 

2,862,523

Net loss per common share, basic and diluted

$

(0.65)

$

(0.32)

$

(4.39)

$

(0.55)

For the nine months ended September 30, 2020 and 2019, potentially dilutive securities excluded from the computations of diluted weighted-average common shares outstanding were (in shares):

    

September 30, 

    

September 30, 

2020

2019

Options to purchase

 

1,484

 

149,309

Restricted Stock Units

36,368

Series A‑1 Preferred Stock

 

624,594

 

602,426

Series B Preferred Stock

 

452,378

 

70,622

Total

 

1,114,824

 

822,357

4.PROPERTY AND EQUIPMENT

Property and equipment consisted of the following at September 30, 2020 and December 31, 2019:

    

September 30, 

    

December 31, 

2020

2019

Equipment

$

736,000

$

488,800

Leasehold improvements

 

1,126,600

 

302,700

Office furniture, fixtures, and equipment

 

16,600

 

16,600

Software

 

151,700

 

141,500

Construction in progress

 

62,000

 

 

2,092,900

 

949,600

Less: Accumulated depreciation

 

(480,600)

 

(361,700)

Total

$

1,612,300

$

587,900

Depreciation expense was $50,400 and $20,700 for the three months ended September 30, 2020 and 2019, respectively, and $118,900 and $63,700 for the nine months ended September 30, 2020 and 2019, respectively. Depreciation expense is allocated between research and development and general and administrative operating expenses on the condensed consolidated statements of operations.

17

Table of Contents

5.ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consisted of the following at September 30, 2020 and December 31, 2019:

    

September 30, 

    

December 31, 

2020

2019

Accrued consulting and outside services

$

435,900

$

221,300

Accrued compensation

 

37,100

 

Total

$

473,000

$

221,300

6.CURRENT LOAN PAYABLE

On May 1, 2020, the Company received a loan in the principal amount of $115,600 (the “SBA Loan”) under the Paycheck Protection Program (“PPP”), which was established under the recently enacted Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) administered by the U.S. Small Business Administration (the “SBA”). The intent and purpose of the PPP is to support companies, during the COVID-19 pandemic, by providing funds for certain specified business expenses, with a focus on payroll. As a qualifying business as defined by the SBA, the Company is using the proceeds from this loan to primarily help maintain its payroll. The term of the SBA Loan promissory note (“the Note”) is two years, though it may be payable sooner in connection with an event of default under the Note. The SBA Loan carries a fixed interest rate of one percent per year, with the first payment due seven months from the date of initial cash receipt. Under the CARES Act and the PPP, certain amounts of loans made under the PPP may be forgiven if the recipients use the loan proceeds for eligible purposes, including payroll costs and certain rent or utility costs, and meet other requirements regarding, among other things, the maintenance of employment and compensation levels. The Company intends to use the SBA Loan for qualifying expenses and to apply for forgiveness of the SBA Loan in accordance with the terms of the CARES Act.

The Note provides for customary events of default, including, among others, those relating to failure to make payment, bankruptcy, materially false or misleading representations to the SBA, and adverse changes in the Company’s financial condition or business operations that may materially affect its ability to pay the SBA Loan.

As the legal form of the Note is a debt obligation, the Company accounts for it as debt under ASC 470, Debt, and recorded $105,600 during the nine months ended September 30, 2020 in the condensed consolidated balance sheet. During the nine months ended September 30, 2020, the Company received initial proceeds of $115,600 and made a repayment of $10,000 on the SBA Loan, bringing the balance to $105,600 as of September 30, 2020. The Company accrues interest over the term of the loan and does not impute additional interest at a market rate because the guidance on imputing interest in ASC 835-30, Interest, excludes transactions where interest rates are prescribed by a government agency. If any amount of the loan is ultimately forgiven, income from the extinguishment of debt would be recognized as a gain on loan extinguishment in the condensed consolidated statement of operations.

7.CONVERTIBLE PROMISSORY NOTES

Starting in June 2016, the Company sold convertible promissory notes to certain investors to help finance its operations. The convertible promissory notes were in amounts ranging from $12,500 to $500,000, earning annual interest between 6% and 17% and all maturities were on June 1, 2019, January 2, 2020, or June 30, 2020 (the “Maturity Date”).

The convertible promissory notes were convertible into shares issued in the Company’s Next Financing Close by dividing the total amount of convertible promissory notes, plus accrued interest (the “Balance”), by the applicable conversion price, as defined in the convertible promissory notes. If the convertible promissory notes have not been converted, the Balance shall be payable in full if the Company consummates a change of control transaction. If there has not been a Next Financing Close or a change in control by the Maturity Date, then at the noteholders’ option, the Company shall either repay the Balance then outstanding or convert into the Company’s common stock at a set conversion price then in effect, as defined in the convertible promissory notes.

The estimated fair value of the conversion discount related embedded derivative was determined using a probability-weighted expected return model. The probability of a Next Financing Close occurring prior to the Maturity Date was determined to be 55% during the nine months ended September 30, 2019. The net present value of the conversion discount related embedded derivative was measured using a discount rate of 25% in the nine months ended

18

Table of Contents

September 30, 2019. There have been no convertible promissory note issuances in the nine months ended September 30, 2020. Below is a table that outlines the initial value of issuances and the bifurcated embedded derivative liability during the nine months ended September 30, 2020 and 2019:

    

September 30, 

    

September 30, 

2020

2019

Convertible promissory notes- issuances

$

$

250,000

Conversion of accounts payable into convertible promissory notes

 

 

134,800

Total issuances and conversions into convertible promissory notes

 

 

384,800

Embedded derivative liability

 

  

 

  

Initial fair value upon issuance of convertible promissory notes

 

 

21,000

Realized and unrealized gains and losses

 

 

2,000

Converted embedded derivative liability into Series A‑1 Preferred Stock

 

 

(23,000)

Embedded derivative liability balance at September 30

$